Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
"Pathogenic bacteria in the colon" refers to any of a large, diverse, and dynamic group of bacterial species capable of causing disease within the human large intestine. These bacteria are not a single entity but a category that includes Gram-negative and Gram-positive organisms such as Escherichia coli (pathogenic strains), Klebsiella pneumoniae, Bacteroides fragilis, Salmonella spp., Shigella spp., Clostridium perfringens, and others[1][2][6]. Pathogenic potential arises from specific virulence factors like toxin production, the ability to invade or damage colonic epithelium, immune evasion, or inflammation induction[2][3]. Their presence can contribute to acute infections (e.g., gastroenteritis), chronic inflammation (e.g., inflammatory bowel disease), and are implicated in colorectal carcinogenesis. There is no single molecular target or structure for all "pathogenic bacteria in colon"—it is a taxonomically and functionally diverse set defined solely by pathogenic capacity and context.\n\nKey limitations: \n- This is not a molecular target but a broad organismal category; it cannot be structurally interrogated, classified, or drugged like a receptor or enzyme.\n- For detailed, actionable drug target information, identification of a specific pathogenic bacterial species or specific virulence factor is necessary.\n\nSummary: \n- "Pathogenic bacteria in colon" is a non-canonical, unspecific designation describing a diverse group of disease-causing bacteria found in the human colon. It is not considered a drug target in the classical, molecular sense[1][2][6].
Antibiotics: Inhibit bacterial cell wall synthesis, protein synthesis, DNA replication, or metabolic pathways leading to bacterial death or stasis\nProbiotics: Compete with pathogens for nutrients and attachment sites; modulate host immune responses; produce antimicrobial substances\nFecal microbiota transplantation: Restores normal microbial community to suppress pathogen expansion
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pathogenic bacteria in colon.